Skip to main content
SpringerLink
Log in

Drug Treatment

  • Chapter
  • First Online:
Neurourology

  • 1149 Accesses

Abstract

Neurogenic lower urinary tract dysfunction (NLUTD) is a heterogeneous combination of symptoms and urodynamic findings that are the result of neurological injury to the bladder (Fig. 27.1) [1–4]. The patterns of bladder storage and voiding disturbances depend on the lesion of neurologic lesion (Fig. 27.2). Patients often have incontinence, urgency, frequency and/or impaired bladder emptying. Urodynamically, there is often poor bladder wall compliance, neurogenic detrusor overactivity (NDO) and/or detrusor sphincter dyssynergia (DSD) which may result in morphological changes in the bladder wall, such as trabeculations and diverticulae. NLUTD can be found in 85–90% of patients with spinal cord injury (SCI), with urinary incontinence occurring in more than 50% NLUTD also occurs in 50–80% of patients with multiple sclerosis (MS), in 27–64% of patients with Parkinson’s disease, and in over 95% of patients with spina bifida [3]. It also occurs frequently with many other neurological conditions such as after stroke, transverse myelitis, and autonomic disorders [1–4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Drake MJ, Apostolidis A, Cocci A, et al. Neurogenic lower urinary tract dysfunction: clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013. Neurourol Urodyn. 2016;35:657–65.

    Article  PubMed  Google Scholar 

  2. Sturm RM, Cheng EY. The management of the pediatric neurogenic bladder. Curr Bladder Dysfunct Rep. 2016;11:225–33.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Tudor KI, Sakakibara R, Panicker JN. Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol. 2016;263:2555–64.

    Article  PubMed  Google Scholar 

  4. Wyndaele JJ. The management of neurogenic lower urinary tract dysfunction after spinal cord injury. Nat Rev Urol. 2016;13:705–14.

    Article  PubMed  Google Scholar 

  5. Abrams P, Cardozo L, Fall M, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.

    Article  PubMed  Google Scholar 

  6. Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56:81–8.

    Article  PubMed  Google Scholar 

  7. Cameron AP, Wallner LP, Tate DG, et al. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol. 2010;184:213–7.

    Article  PubMed  Google Scholar 

  8. Borau A, Adot JM, Allué M, et al. A systematic review of the diagnosis and treatment of patients with neurogenic hyperactivity of the detrusor muscle. Actas Urol Esp. 2017;42:5–16.

    Article  PubMed  Google Scholar 

  9. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Andersson KE. Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol. 2011;202:319–44.

    Article  CAS  Google Scholar 

  11. Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Phys. 1998;275:1654–60.

    Google Scholar 

  12. Pontari MA, Braverman AS, Ruggieri MR Sr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Phys. 2004;286:874–80.

    Google Scholar 

  13. Schneider T, Hein P, Michel-Reher M, et al. Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. Naunyn Schmiedeberg's Arch Pharmacol. 2005a;372:71–8.

    Article  CAS  Google Scholar 

  14. Schneider T, Hein P, Bai J, et al. A role for muscarinic receptors or rho-kinase in hypertension associated rat bladder dysfunction? J Urol. 2005b;173:2178–81.

    Article  CAS  PubMed  Google Scholar 

  15. Yoshida M, Homma Y, Inadome A, et al. Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles. Exp Gerontol. 2001;3:99–109.

    Article  Google Scholar 

  16. Yoshida M, Masunaga K, Satoji Y, et al. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance. J Pharmacol Sci. 2008;106:193–8.

    Article  CAS  PubMed  Google Scholar 

  17. Rapp DE, Lyon MB, Bales GT, et al. A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction. Eur Urol. 2005;48:303–8.

    Article  CAS  PubMed  Google Scholar 

  18. Datta SN, Roosen A, Pullen A, et al. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol. 2010;184:2578–85.

    Article  CAS  PubMed  Google Scholar 

  19. Andersson KE, Cardozo L, Cruz F, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, et al, editors. 6th International Consultation on Incontinence, Tokyo, September 2016, The International Continence Society (ICS) and the International Consultation on Urological Diseases (ICUD). 2017.

    Google Scholar 

  20. Madhuvrata P, Singh M, Hasafa Z, et al. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012;62:816–30.

    Article  CAS  PubMed  Google Scholar 

  21. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Naja M, Zmudka J, Hannat S, et al. In geriatric patients, delirium symptoms are related to the anticholinergic burden. Geriatr Gerontol Int. 2016;16:424–31.

    Article  PubMed  Google Scholar 

  23. Moga DC, Abner EL, Wu Q, et al. Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y). 2017;3:139–48.

    Google Scholar 

  24. Esin E, Ergen A, Cankurtaran M, et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. Aging Ment Health. 2015;19:217–23.

    Article  PubMed  Google Scholar 

  25. Swami S, Cohen RA, Kairalla JA, et al. Anticholinergic drug use and risk to cognitive performance in older adults with questionable cognitive impairment: a cross-sectional analysis. Drugs Aging. 2016;33:809–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51:432–41.

    Article  CAS  PubMed  Google Scholar 

  27. Horstmann M, Schaefer T, Aguilar Y, et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn. 2006;25:441–5.

    Article  CAS  PubMed  Google Scholar 

  28. Amend B, Hennenlotter J, Schäfer T, et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol. 2008;53:1021–8.

    Article  CAS  PubMed  Google Scholar 

  29. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol. 1997;157:1093–7.

    Article  CAS  PubMed  Google Scholar 

  30. Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol. 1988;140:47–50.

    Article  CAS  PubMed  Google Scholar 

  31. Kennelly MJ. A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010;12:12–9.

    PubMed  PubMed Central  Google Scholar 

  32. Jirschele K, Sand PK. Oxybutynin: past, present, and future. Int Urogynecol J. 2013;24:595–604.

    Article  PubMed  Google Scholar 

  33. Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995;6:243–62.

    Article  CAS  PubMed  Google Scholar 

  34. Thüroff JW, Chartier-Kastler E, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol. 1998;16:S48–61.

    Article  PubMed  Google Scholar 

  35. Hussain RM, Hartigan-Go K, Thomas SHL, et al. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol. 1994;37:485.

    Google Scholar 

  36. Arisco AM, Brantly EK, Kraus SR. Oxybutynin extended release for the management of overactive bladder: a clinical review. Drug Des Devel Ther. 2009;3:151–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78:696.

    Article  CAS  PubMed  Google Scholar 

  38. Siddiqui MA, Perry CM, Scott LJ. Oxybutynin extended- release: a review of its use in the management of overactive bladder. Drugs. 2004;64:885.

    Article  CAS  PubMed  Google Scholar 

  39. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62:1792–800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Pagoria D, O'Connor RC, Guralnick ML. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep. 2011;12:351–7.

    Article  PubMed  Google Scholar 

  41. Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs. 1998;55:813–20.

    Article  CAS  PubMed  Google Scholar 

  42. Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging. 2001;18:277–304.

    Article  CAS  PubMed  Google Scholar 

  43. Salvatore S, Serati M, Bolis P. Tolterodine for the treatment of overactive bladder. Expert Opin Pharmacother. 2008;9:1249–55.

    Article  CAS  PubMed  Google Scholar 

  44. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57:414–21.

    Article  PubMed  Google Scholar 

  45. Watanabe M, Yamanishi T, Honda M, et al. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder. Int J Urol. 2010;17:931–6.

    Article  CAS  PubMed  Google Scholar 

  46. Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007;81:377–85.

    Article  CAS  PubMed  Google Scholar 

  47. Fusgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther. 2000;38:223.

    Article  CAS  PubMed  Google Scholar 

  48. Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44:701.

    Article  CAS  PubMed  Google Scholar 

  49. Kim Y, Yoshimura N, Masuda H, et al. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology. 2005;65:238–42.

    Article  PubMed  Google Scholar 

  50. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64:1294–300.

    Article  CAS  PubMed  Google Scholar 

  51. Chancellor MB, Staskin DR, Kay GG, et al. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29:259–73.

    Article  CAS  PubMed  Google Scholar 

  52. Stöhrer M, Bauer P, Giannetti BM, et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries: a multicentre placebo controlled double-blind trial. Urol Int. 1991;47:138.

    Article  PubMed  Google Scholar 

  53. Madersbacher H, Stohrer M, Richter R, et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol. 1995;75:452.

    Article  CAS  PubMed  Google Scholar 

  54. Allousi S, Laval K-U, Eckert R. Trospium chloride (Spasmolyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. J Clin Res. 1998;1:439.

    Google Scholar 

  55. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392.

    CAS  PubMed  Google Scholar 

  56. Zinner N, Gittelman M, Harris R, et al. Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004a;171:2311.

    Article  CAS  PubMed  Google Scholar 

  57. Bödeker RH, Madersbacher H, Neumeister C, et al. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol. 2010;10:15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Silver N, Sandage B, Sabounjian L, et al. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride20 mg in healthy adults. J Clin Pharmacol. 2010;50:143–50.

    Article  CAS  PubMed  Google Scholar 

  59. Staskin DR, Rosenberg MT, Sand PK, et al. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009;63:1715–23.

    Article  CAS  PubMed  Google Scholar 

  60. Haruno A. Inhibitory effects of propiverine hydrochloride on the agonist-induced or spontaneous contractions of various isolated muscle preparations. Arzneimittelforschung. 1992;42:815–7.

    CAS  PubMed  Google Scholar 

  61. Wuest M, Weiss A, Waelbroeck M, et al. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedeberg's Arch Pharmacol. 2006;374:87–97.

    Article  CAS  Google Scholar 

  62. Madersbacher H, Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol. 2001;19:324–35.

    Article  CAS  PubMed  Google Scholar 

  63. McKeage K. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. Clin Drug Investig. 2013;33:71–91.

    Article  CAS  PubMed  Google Scholar 

  64. Stöhrer M, Mürtz G, Kramer G, et al. Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity. Spinal Cord. 2013;51:419–23.

    Article  PubMed  Google Scholar 

  65. Sakakibara R, Ogata T, Uchiyama T, et al. How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatr Soc. 2009;57:1515–7.

    Article  PubMed  Google Scholar 

  66. Oelke M, Murgas S, Schneider T, et al. Influence of propiverine ER 30 mg once daily on cognitive function in elderly female and male patients with overactive bladder: a non-interventional study to assess real life data. In 43rd Annual Meeting of the ICS, Barcelona, 2013.

    Google Scholar 

  67. Schulte-Baukloh H, Mürtz G, Henne T, et al. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis. BJU Int. 2006;97:355–8.

    Article  PubMed  Google Scholar 

  68. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology in lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Urology. 2003;61:37–49.

    Article  PubMed  Google Scholar 

  69. Stewart W, Herzog R, Wein A. at al. The prevalence and impact of overactive bladder in the US: results from NOBLE program. Neurourol Urodyn. 2001;20:406–8.

    Google Scholar 

  70. Milsom I, Abrams P, Cardozo L, Robert RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study. BJU Int. 2001;87:760–6.

    Article  CAS  PubMed  Google Scholar 

  71. VESIcare [package insert]. Deerfield, II1: Astellas Pharma US, Inc; 2004.

    Google Scholar 

  72. Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48:281–302.

    Article  CAS  PubMed  Google Scholar 

  73. Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol. 2004;44:1023–33.

    Article  CAS  PubMed  Google Scholar 

  74. Smulders RA, Smith NN, Krauwinkel WJ, et al. Pharmacokinetics, Safety, and Tolerability of Solifenacin in Patients with Renal Insufficiency. J Pharmacol Sci. 2007;103:67–74.

    Article  CAS  PubMed  Google Scholar 

  75. Kuipers M, Smulders R, Krauwinkel W, et al. Open-Label Study of the Safety and Pharmacokinetics of Solifenacin in Subjects with Hepatic Impairment. J Pharmacol Sci. 2006;102:405–12.

    Article  CAS  PubMed  Google Scholar 

  76. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004;56:581–631.

    Article  CAS  PubMed  Google Scholar 

  77. Sigala S, Mirabella G, Peroni A, et al. Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology. 2002;60:719–25.

    Article  PubMed  Google Scholar 

  78. Chess-Williams R, Chapple CR, Yamanishi T, et al. The minor population of M3-receptors mediates contraction of human detrusor muscle in vitro. J Auton Pharmacol. 2002;21:1–6.

    Google Scholar 

  79. Golan DE, Tashjian AH, Armstrong EJ, et al. Principles of Pharmacology. The Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins: Baltimore, Md; 2005.

    Google Scholar 

  80. Caulfield MP, Birdsall NJM. International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50:279–90.

    CAS  PubMed  Google Scholar 

  81. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther. 1995;273:959–66.

    CAS  PubMed  Google Scholar 

  82. Nakamura T, Kimura J, Yamaguchi O. Muscarinic M2 receptors inhibit Ca2+−activated K+ channels in rat bladder smooth muscle. Int J Urol. 2002;9:689–96.

    Article  CAS  PubMed  Google Scholar 

  83. Pontari MA, Braverman AS, Sr RM, et al. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol. 2004;286:874–80.

    Article  Google Scholar 

  84. Swart PJ, Krauwinkel WJ, Smulders RA, et al. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol. 2006;99:33–6.

    Article  CAS  PubMed  Google Scholar 

  85. Taekema-Roelvink ME, Swart PJ, Kuipers ME, et al. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Clin Ther. 2005;27:1403–10.

    Article  CAS  PubMed  Google Scholar 

  86. Michel MC, Minematsu T, Hashimoto T, et al. In vitro studies on the potential of solifenacin for drug-drug interaction: plasma protein and MDR 1 transport. Br J Clin Pharmacol. 2015;59:647.

    Google Scholar 

  87. Govier FE, Smith N, Uchida T. Efficacy and safety of 10 mg solifenacin succinate in patients with overactive bladder syndrome: results from a randomized, double-blind, placebo-controlled phase III pivotal trial. Clin Med Insights Urol. 2010;4:11–20.

    CAS  Google Scholar 

  88. Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007;100:579–87.

    Article  CAS  PubMed  Google Scholar 

  89. Chapple C, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303–10.

    Article  CAS  PubMed  Google Scholar 

  90. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464–70.

    Article  CAS  PubMed  Google Scholar 

  91. Cardozo L, Lisec M, Millard R. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919–24.

    Article  CAS  PubMed  Google Scholar 

  92. Kelleher C, Cardozo L, Chapple C. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005;95:81–5.

    Article  PubMed  Google Scholar 

  93. Cardozo L, Amarenco G, Pushkar G, et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU Int. 2013;111:804–10.

    Article  CAS  PubMed  Google Scholar 

  94. Steers WD. Darifenacin: Pharmacology and clinical usage. Urol Clin North Am. 2006;33:475–82.

    Article  PubMed  Google Scholar 

  95. Smith PP, Lai HH, Appell RA. Darifenacin: a selective M3 muscarinic receptor antagonist for the treatment of overactive bladder. Therapy. 2006;3:723–32.

    Article  CAS  Google Scholar 

  96. Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45:325–50.

    Article  CAS  PubMed  Google Scholar 

  97. Carl S, Laschke S. Darifenacin is also effective in neurogenic bladder dysfunction (multiple sclerosis). Urology. 2006;68:250.

    Article  Google Scholar 

  98. Bycroft J, Leaker B, Wood S, et al. The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury. Neurourol Urodyn. 2003;22:A190.

    Google Scholar 

  99. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int. 2006;98:1025–32.

    Article  CAS  PubMed  Google Scholar 

  100. Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72:235–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int. 2005;96:1055–62.

    Article  CAS  PubMed  Google Scholar 

  102. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agent’s darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50:317–26.

    Article  CAS  PubMed  Google Scholar 

  103. Wesnes K, Lipton R, Kolodner K, et al. Darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderly volunteers. Eur Urol. 2004;3:131.

    Article  Google Scholar 

  104. Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants & gt; or = 50 years. J Cardiovascular Pharmacol Ther. 2008;13:241–51.

    Article  CAS  Google Scholar 

  105. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166:140.

    Article  CAS  PubMed  Google Scholar 

  106. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol. 2005;23:263.

    Article  CAS  PubMed  Google Scholar 

  107. Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur Urol. 2007;51:907.

    Article  CAS  PubMed  Google Scholar 

  108. Sahai A, Mallina R, Dowson C, et al. Evolution of transdermal oxybutynin in the treatment of overactive bladder. Int J Clin Pract. 2008;62:167.

    Article  CAS  PubMed  Google Scholar 

  109. Staskin DR, Salvatore S. Oxybutynin topical and transdermal formulations: an update. Drugs Today (Barc). 2010;46:417–25.

    Article  CAS  Google Scholar 

  110. Cartwright R, Srikrishna S, Cardozo L, et al. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermaloxybutynin for the treatment of urgency and urge incontinence. BJU Int. 2011;107:70–6.

    Article  CAS  PubMed  Google Scholar 

  111. Gleason JM, Daniels C, Williams K, et al. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration. J Pediatr Urol. 2014;10:753–7.

    Article  PubMed  Google Scholar 

  112. Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009;181:1764–72.

    Article  CAS  PubMed  Google Scholar 

  113. Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother. 2009;10:3103–11.

    Article  CAS  PubMed  Google Scholar 

  114. Dmochowski RR, Newman DK, Sand PK, et al. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clin Drug Investig. 2011;31:559–71.

    Article  CAS  PubMed  Google Scholar 

  115. Sand PK, Davila GW, Lucente VR, et al. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012;206:168.e1–6.

    Article  CAS  Google Scholar 

  116. Fader M, Glickman S, Haggar V, et al. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol. 2007;177:208–13.

    Article  CAS  PubMed  Google Scholar 

  117. Humblet M, Verpoorten C, Christiaens MH, et al. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourol Urodyn. 2015;34:336–42.

    Article  CAS  PubMed  Google Scholar 

  118. Fröhlich G, Burmeister S, Wiedemann A, et al. Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test. Arzneimittelforschung. 1998;48:486.

    PubMed  Google Scholar 

  119. Walter P, Grosse J, Bihr AM, et al. Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: a pilot study. Neurourol Urodyn. 1999;18:447–53.

    Article  CAS  PubMed  Google Scholar 

  120. Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30:292–301.

    Article  CAS  PubMed  Google Scholar 

  121. Giuliano F, Ückert S, Maggi M, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013;63:506–16.

    Article  CAS  PubMed  Google Scholar 

  122. Cellek S, Cameron NE, Cotter MA, et al. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nat Rev Urol. 2014;11:231–41.

    Article  CAS  PubMed  Google Scholar 

  123. Behr-Roussel D, Oger S, Caisey S, et al. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol. 2010;59:272–9.

    Article  PubMed  CAS  Google Scholar 

  124. Morelli A, Filippi S, Sandner P, et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med. 2009b;6:1594–608.

    Article  CAS  PubMed  Google Scholar 

  125. Nomiya M, Burmeister DM, Sawada N, et al. Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol. 2013;189:754–61.

    Article  CAS  PubMed  Google Scholar 

  126. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1401–7.

    Article  CAS  PubMed  Google Scholar 

  127. Roehrborn CG, McVary KT, Elion-Mboussa A, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180:1228–34.

    Article  CAS  PubMed  Google Scholar 

  128. Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61:917–25.

    Article  CAS  PubMed  Google Scholar 

  129. Gacci M, Andersson KE, Chapple C, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016;70:124–33.

    Article  CAS  PubMed  Google Scholar 

  130. Cameron AP, Clemens JQ, Latini JM, et al. Combination drug therapy improves compliance of the neurogenic bladder. J Urol. 2009;182:1062–7.

    Article  PubMed  Google Scholar 

  131. Gacci M, Vittori G, Tosi N, et al. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9:1624–33.

    Article  CAS  PubMed  Google Scholar 

  132. Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2013;189:S135–40.

    CAS  PubMed  Google Scholar 

  133. Andersson K-E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev. 1993;45:253–308.

    Google Scholar 

  134. Nergårdh A, Boréus LO, Naglo AS. Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol. 1977;40:14–21.

    Article  Google Scholar 

  135. Larsen JJ. Alpha and beta-adrenoceptors in the detrusor muscle and bladder base of the pig and beta-adrenoceptors in the detrusor muscle of man. Br J Pharmacol. 1979;65:215–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Emorine LJ, Marullo S, Briend-Sutren MM, et al. Molecular characterization of the human beta 3-adrenergic receptor. Science. 1989;245:1118–21.

    Article  CAS  PubMed  Google Scholar 

  137. Igawa Y, Michel MC. Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedeberg's Arch Pharmacol. 2013;386:177–83.

    Article  CAS  Google Scholar 

  138. Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol. 1999;126:819–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Takeda M, Obara K, Mizusawa T, et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther. 1999;288:1367–73.

    CAS  PubMed  Google Scholar 

  140. Fujimura K, Tamura K, Tsutsumi T, et al. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol. 1999;161:680–5.

    Article  CAS  PubMed  Google Scholar 

  141. Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedeberg's Arch Pharmacol. 2008;377:473–81.

    Article  CAS  Google Scholar 

  142. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170:649–53.

    Article  CAS  PubMed  Google Scholar 

  143. Igawa Y, Yamazaki Y, Takeda H, et al. Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol. 2001;165:240–4.

    Article  CAS  PubMed  Google Scholar 

  144. Igawa Y, Aizawa N, Homma Y. Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol. 2010;51:811–8.

    Article  PubMed  PubMed Central  Google Scholar 

  145. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147:S88–119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Hudman D, Elliott RA, Norman RI. K(ATP) channels mediate the beta(2)-adrenoceptor agonist-induced relaxation of rat detrusor muscle. Eur J Pharmacol. 2000;397:169–76.

    Article  CAS  PubMed  Google Scholar 

  147. Frazier EP, Mathy MJ, Peters SL, et al. Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol? J Pharmacol Exp Ther. 2005;313:260–6.

    Article  CAS  PubMed  Google Scholar 

  148. Frazier EP, Peters SLM, Braverman AS, et al. Signal transduction underlying control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol. 2008;377:449–62.

    Article  CAS  Google Scholar 

  149. Uchida H, Shishido K, Nomiya M, et al. Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via beta-adrenoceptors. Eur J Pharmacol. 2005;518:195–202.

    Article  CAS  PubMed  Google Scholar 

  150. Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006;98:1310–4.

    Article  CAS  PubMed  Google Scholar 

  151. Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl) amino]ethyl}acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321:642–7.

    Article  CAS  PubMed  Google Scholar 

  152. Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62:1165–73.

    Article  CAS  PubMed  Google Scholar 

  153. Gillespie JI, Palea S, Guilloteau V, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int. 2012;110:E132–42.

    Article  CAS  PubMed  Google Scholar 

  154. Hatanaka T, Ukai M, Watanabe M, et al. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. Naunyn Schmiedeberg's Arch Pharmacol. 2013;386:247–53.

    Article  CAS  Google Scholar 

  155. Michel MC, Igawa Y. Therapeutic targets for overactive bladder other than smooth muscle. Expert Opin Ther Targets. 2015;19:687–705.

    Article  CAS  PubMed  Google Scholar 

  156. Rouget C, Rekik M, Camparo P, et al. Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder. Pharmacol Res. 2014;80:14–20.

    Article  CAS  PubMed  Google Scholar 

  157. D’Agostino G, Condino AM, Calvi P. Involvement of β-adrenoceptors in the inhibitory control 3 of cholinergic activity in human bladder: direct evidence 3 by [H]-acetylcholine release experiments in the isolated detrusor. Eur J Pharmacol. 2015;758:115–22.

    Article  PubMed  CAS  Google Scholar 

  158. Birder LA, Nealen ML, Kiss S, et al. Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci. 2002;22:8063–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Murakami S, Chapple CR, Akino H, et al. The role of the urothelium in mediating bladder responses to isoprenaline. BJU Int. 2007;99:669–73.

    Article  CAS  PubMed  Google Scholar 

  160. Masunaga K, Chapple CR, McKay NG, et al. The β3-adrenoceptor mediates the inhibitory effects of β-adrenoceptor agonists via the urothelium in pig bladder dome. Neurourol Urodyn. 2010;29:1320–5.

    Article  CAS  PubMed  Google Scholar 

  161. Woods M, Carson N, Norton NW, Sheldon JH, Argentieri TM. Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol. 2001;166:1142–7.

    Article  CAS  PubMed  Google Scholar 

  162. Takeda H, Yamazaki Y, Igawa Y, et al. Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn. 2002;21:558–65.

    Article  CAS  PubMed  Google Scholar 

  163. Kaidoh K, Igawa Y, Takeda H, et al. Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol. 2002;168:1247–52.

    Article  CAS  PubMed  Google Scholar 

  164. Hicks A, McCafferty GP, Riedel E, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007;323:202–9.

    Article  CAS  PubMed  Google Scholar 

  165. Eltink C, Lee J, Schaddelee M, et al. Single dose pharmacokinetics and absolute bioavailibility of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012;50:838–50.

    Article  CAS  PubMed  Google Scholar 

  166. Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic properties of mirabegron, a β(3)-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012;34:2144–60.

    Article  CAS  PubMed  Google Scholar 

  167. Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012a;40:815–24.

    Article  CAS  PubMed  Google Scholar 

  168. Füllhase C, Soler R, Westerling-Andersson K, et al. Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction. Neurourol Urodyn. 2011;30:1382–7.

    PubMed  Google Scholar 

  169. Takusagawa S, Yajima K, Miyashita A, et al. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β(3)-adrenoceptor agonist. Xenobiotica. 2012b;42:957–67.

    Article  CAS  PubMed  Google Scholar 

  170. Takusagawa S, Miyashita A, Iwatsubo T, et al. In vitro inhibition and induction of human cytochrome P450 enzymes bymirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica. 2012c;42:1187–96.

    Article  CAS  PubMed  Google Scholar 

  171. Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33:17–30.

    Article  CAS  PubMed  Google Scholar 

  172. Cui Y, Zong H, Yang C, et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014;46:275–84.

    Article  CAS  PubMed  Google Scholar 

  173. Rossanese M, Novara G, Challacombe B, et al. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB). BJU Int. 2015;115:32–40.

    Article  CAS  PubMed  Google Scholar 

  174. Suarez O, Osborn D, Kaufman M, et al. Mirabegron for male lower urinary tract symptoms. Curr Urol Rep. 2013;14:580–4.

    Article  PubMed  Google Scholar 

  175. Otsuki H, Kosaka T, Nakamura K, et al. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol. 2013;45:53–60.

    Article  CAS  PubMed  Google Scholar 

  176. Abrams P, Kelleher C, Staskin D. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67:577–88.

    Article  CAS  PubMed  Google Scholar 

  177. Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinalcord injury. Spinal Cord. 2016;54:78–82.

    Article  PubMed  Google Scholar 

  178. Wada N, Okazaki S, Kobayashi S, et al. Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation. Hinyokika Kiyo. 2015;61:7–11.

    PubMed  Google Scholar 

  179. Kamei J, Furuta A, Akiyama Y, et al. Video-urodynamic effects of mirabegron, a β3-adrenoceptor agonist, in patients with low-compliance bladder. Int J Urol. 2015;22:956–61.

    Article  CAS  PubMed  Google Scholar 

  180. Thiagamoorthy G, Giarenis I, Cardozo L. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome. Expert Opin Investig Drugs. 2015;24:1299–306.

    Article  CAS  PubMed  Google Scholar 

  181. Thiagamoorthy G, Cardozo L, Robinson D. Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother. 2016;17:1317–25.

    Article  CAS  PubMed  Google Scholar 

  182. Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012;62:834–40.

    Article  CAS  PubMed  Google Scholar 

  183. Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609–23.

    Article  CAS  PubMed  Google Scholar 

  184. Di Salvo J, Nagabukuro H, Wickham LA, et al. Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. J Pharmacol Exp Ther. 2017;360:346–55.

    Article  PubMed  CAS  Google Scholar 

  185. Abrams P, Amarenco G, Bakke A, et al. European Tamsulosin Neurogenic Lower Urinary Tract Dysfunction Study Group. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol. 2003;170:1242–51.

    Article  PubMed  Google Scholar 

  186. Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol. 2016;5:51–62.

    PubMed  PubMed Central  Google Scholar 

  187. Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007;4:368–78.

    Article  CAS  PubMed  Google Scholar 

  188. Moon KH, Park CH, Jung HC, et al. A 12-week, open label, multi-center study to evaluate the clinical efficacy and safety of silodosin on voiding dysfunction in patients with neurogenic bladder. Low Urin Tract Symptoms. 2015;7:27–31.

    Article  CAS  PubMed  Google Scholar 

  189. Swierzewski SJ 3rd, Gormley EA, Belville WD, et al. The effect of terazosin on bladder function in the spinal cord injured patient. J Urol. 1994;151:951–4.

    Article  PubMed  Google Scholar 

  190. Yasuda K, Yamanishi T, Kawabe K, Ohshima H, Morita T. The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. J Urol. 1996;156:1125–30.

    Article  CAS  PubMed  Google Scholar 

  191. O'Riordan JI, Doherty C, Javed M, et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol. 1995;153:1114–6.

    Article  CAS  PubMed  Google Scholar 

  192. Kakizaki H, Ameda K, Kobayashi S, et al. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol. 2003;10:576–81.

    Article  CAS  PubMed  Google Scholar 

  193. Krum H, Louis WJ, Brown DJ, et al. A study of the alpha-1 adrenoceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients. Clin Auton Res. 1992;2:83–8.

    Article  CAS  PubMed  Google Scholar 

  194. Chancellor MB, Erhard MJ, Hirsch IH, et al. Prospective evaluation of terazosin for the treatment of autonomic dysreflexia. J Urol. 1994;151:111–3.

    Article  CAS  PubMed  Google Scholar 

  195. Phillips AA, Elliott SL, Zheng MM, et al. Selective alpha adrenergic antagonist reduces severity of transient hypertension during sexual stimulation after spinal cord injury. J Neurotrauma. 2015;15(32):392–6.

    Article  Google Scholar 

  196. Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008;62:1547–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  197. Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf. 2014;13:1187–97.

    Article  CAS  PubMed  Google Scholar 

  198. de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997;50:36–52.

    Article  PubMed  Google Scholar 

  199. Taylor MC, Bates CP. A double-blind crossover trial of baclofen--a new treatment for the unstable bladder syndrome. Br J Urol. 1979;51:504.

    Article  CAS  PubMed  Google Scholar 

  200. Ochs GA. Intrathecal baclofen. Baillieres Clin Neurol. 1993;2:73–86.

    CAS  PubMed  Google Scholar 

  201. Bushman W, Steers WD, Meythaler JM. Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn. 1993;12:163.

    Article  CAS  PubMed  Google Scholar 

  202. Szollar S, North J, Chung J. Antidiuretic hormone levels and polyuria in spinal cord injury. A preliminary report. Paraplegia. 1995;33:94–7.

    CAS  PubMed  Google Scholar 

  203. Zahariou A, Karagiannis G, Papaioannou P, et al. The use of desmopressin in the management of nocturnal enuresis in patients with spinal cord injury. Eura Medicophys. 2007;43:333–8.

    CAS  PubMed  Google Scholar 

  204. Horowitz M, Combs AJ, Gerdes D. Desmopressin for nocturnal incontinence in the spina bifida population. J Urol. 1997;158:2267–8.

    Article  CAS  PubMed  Google Scholar 

  205. Del Gado R, Aceto G, Del Gaizo D, et al. Desmopressin for the treatment of nocturnal bedwetting in patients with neural tube closure defects. J Urol. 2004;171:1656–8.

    Article  PubMed  Google Scholar 

  206. Chancellor MB, Rivas DA, Staas WE Jr. DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury: preliminary report. J Am Paraplegia Soc. 1994;17:165–7.

    Article  CAS  PubMed  Google Scholar 

  207. Bosma R, Wynia K, Havlíková E, et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand. 2005;112:1–5.

    Article  CAS  PubMed  Google Scholar 

  208. Valiquette G, Herbert J, Maede-D’Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol. 1996;53:1270–5.

    Article  CAS  PubMed  Google Scholar 

  209. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84:935–86.

    Article  CAS  PubMed  Google Scholar 

  210. Barendrecht MM, Oelke M, Laguna MP, et al. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int. 2007;99:749.

    Article  CAS  PubMed  Google Scholar 

  211. Alhasso A, Glazener CMA, Pickard R, et al. Adrenergic drugs for urinary incontinence in adults (Review). Cochrane Database for Systematic Reviews. 2005;3:art. No. CD001842.

    Google Scholar 

  212. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual- serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000;40:161.

    Article  CAS  PubMed  Google Scholar 

  213. Thor KB, Kirby M, Viktrup L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract. 2007;61:1349–55.

    Article  CAS  PubMed  Google Scholar 

  214. Hurley DJ, Turner CL, Yalcin I, et al. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol. 2006;125:120–8.

    Article  CAS  PubMed  Google Scholar 

  215. Vella M, Duckett J, Basu M. Duloxetine 1 year on: the long term outcome of a cohort of women prescribed duloxetine. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:961–4.

    Article  PubMed  Google Scholar 

  216. Bump RC, Voss S, Beardsworth A, et al. Long-term efficacy of duloxetine in women with stress urinary incontinence. BJU Int. 2008;102:214–8.

    Article  CAS  PubMed  Google Scholar 

  217. Kaneko K, Fujinaga S, Ohtomo Y, et al. Combined pharmacotherapy for nocturnal enuresis. Pediatr Nephrol. 2001;16:662–4.

    Article  CAS  PubMed  Google Scholar 

  218. Natalin R, Reis LO, Alpendre C, et al. Triple therapy in refractory detrusor overactivity: a preliminary study. World J Urol. 2010;28:79–85.

    Article  PubMed  Google Scholar 

  219. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY). World J Urol. 2017;35:827–38.

    Article  CAS  PubMed  Google Scholar 

  220. Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 2015;116:612–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

    Yasuhiko Igawa

  2. VM Medical College, Safdarjang Hospital, Delhi, India

    Pawan Vasudeva

  3. Department of Urology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

    Waleed Altaweel

  4. Department of Urology, University Hospital, Innsbruck, Austria

    Helmut Madersbacher

  5. Department of Clinical Medicine, University of Aarhus, Aarhus, Denmark

    Karl-Erik Andersson

Authors
  1. Karl-Erik Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helmut Madersbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Waleed Altaweel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pawan Vasudeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasuhiko Igawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl-Erik Andersson .

Editor information

Editors and Affiliations

  1. Department of Urology, China Rehabiliation Research Center Capital Medical University, Beijing, China

    Limin Liao

  2. Department of Urology, University Hospital, Innsbruck, Austria

    Helmut Madersbacher

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature B.V.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Andersson, KE., Madersbacher, H., Altaweel, W., Vasudeva, P., Igawa, Y. (2019). Drug Treatment. In: Liao, L., Madersbacher, H. (eds) Neurourology. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7509-0_27

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-7509-0_27

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-017-7507-6

  • Online ISBN: 978-94-017-7509-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation